Hetero
Denis Adamchik's work experience includes serving as the Head of Business Development at Hetero since April 2022. Prior to this, they were the Chief Executive Director at Belalek since August 2016. Denis also worked as a Researcher at the Research Institute for Physical and Chemical Problems BSU from 2005 to December 2017. Additionally, Denis was the Deputy Director of the Pharmaceutical Activity at Unitehprom BSU from September 2014 to July 2016, and the Head of the Pharmaceutical Department at Unitehprom BSU from February 2012 to September 2014.
Denis Adamchik holds an Executive MBA from Kozminski University, which they pursued from 2019 to 2021. Prior to that, they obtained a Master of Chemistry degree in Polymer Chemistry from Belorussian State University, where they studied from 2004 to 2010. In addition to their formal education, Denis has a certification for their participation in the seminar "Certification of the production of drugs for compliance with GMP," although details about the institution, month, and year of obtaining the certification were not provided.
This person is not in any teams
This person is not in any offices
Hetero
4 followers
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Backed by 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products. Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, approved by stringent global regulatory authorities. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc. Hetero has a strong global presence in over 145+ countries and focusses on making affordable medicines accessible to patients worldwide.